secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-09-10T12:17:34+00:00
Accession:  0001129928-26-000055
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics announces positive preclinical results for pelareorep with pan-RAS inhibitor in colorectal cancer
--------------------------------------------------------------------------------

- Pelareorep + pan-RAS inhibitor reduced tumor growth vs control in RAS-driven colorectal cancer model.
- Greatest tumor reductions in RAS inhibitor and combination groups; no antagonism between therapies.
- Findings support further evaluation of optimized pelareorep dosing with RAS inhibitors to delay resistance.
- Company plans expanded preclinical studies across dosing schedules and RAS-driven tumor models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/0001129928-26-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/oncy-20260910.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer